How to read peptide research

If you’re researching a peptide and search PubMed, you’ll find anything from cell-culture experiments to thousand-patient clinical trials, all returned by the same search box. They are not equivalent. This article is a field guide to sorting through what you find.

The hierarchy of evidence

Not all studies carry the same weight. A rough ranking, from weakest to strongest:

1. In vitro (cell or tissue culture). A compound does something to isolated cells. Useful for mechanism hypotheses, weak evidence for whole-organism effects.
2. Animal models (usually mice or rats). A compound does something to a living organism with roughly human-similar biology. Useful, but many effects seen in rodents fail to replicate in humans.
3. Phase 1 human trials. Small (20–80 people), primarily safety and pharmacokinetics. The question is whether humans tolerate it and what happens to it in the body.
4. Phase 2 human trials. Medium-sized (100–300 people), first test of efficacy. Effect sizes here should be treated with caution because of small-sample bias.
5. Phase 3 trials. Large (often thousands), confirming efficacy and monitoring adverse effects under realistic conditions.
6. Post-market surveillance and systematic reviews. The strongest evidence comes from pooling many trials and watching drugs in real-world use over years.

A peptide with a striking rodent effect and no human data should excite you about the mechanism and leave you skeptical about claims of human benefit. Rodent-to-human translation is low.

Who ran the study?

Independent replication matters. When the majority of publications on a compound come from a single laboratory or a small collaborative network, the evidence base is more fragile than the raw publication count suggests. Look for:

• Studies from multiple independent groups.
• Cross-country replication.
• Registered trials (with a ClinicalTrials.gov NCT number) rather than retrospective case series.

What is the outcome being measured?

“Significant improvement” can mean very different things. Distinguish:

• Surrogate endpoints: a biomarker that should correlate with a clinical outcome (e.g., HbA1c for diabetes, IGF-1 for GH activity). Useful, but biomarkers sometimes move without the outcome following.
• Clinical endpoints: something a patient would notice — weight loss, cardiovascular events, survival, quality of life.
• Composite endpoints: combinations (e.g., “major adverse cardiovascular events”). Check the component results, not just the composite.

A peptide that improves a biomarker in a small trial is hypothesis-generating. A peptide that improves a hard clinical endpoint in a large trial is a drug.

Effect sizes vs. p-values

A study can have a statistically significant result that is clinically trivial. Two things to check:

• Absolute effect size. How much better is the treated group? If weight loss is 2% vs. 1% with placebo, the difference may be real but unimpressive.
• Confidence interval. A wide 95% CI tells you the effect could be much smaller (or larger) than the point estimate suggests.

Funding and conflicts

The best journals require authors to declare financial relationships. Industry funding doesn’t invalidate findings, but it’s one of several signals to weigh — especially for marginal effect sizes.

Red flags

• Marketing claims not linked to any published study.
• Claims referencing “studies” without titles, DOIs, or PMIDs.
• Clinical-sounding claims backed only by rodent experiments.
• Single-lab evidence with no independent replication over many years.
• Trial registrations that were started but never published results.

Green flags

• Pre-registered trial protocols.
• Multiple independent replications.
• Large, well-powered Phase 3 data.
• Findings that survived meta-analysis.
• Consistent mechanism across in vitro, animal, and human studies.

A short rule of thumb

If you’re about to believe something about a peptide, ask: which kind of study showed that, how many people or animals, and has it been independently reproduced? The three questions take less than a minute to answer and will sharpen almost any claim you encounter.